




## Receptos: Autoimmune Clinical Pipeline Combined with Transformational GPCR Discovery Technology Platform

Receptos is a small molecule drug discovery and development company that leverages proprietary GPCR cell- and protein-based screening with receptor structure determination to enable rational drug development for high-value GPCR targets. Receptos has exclusively licensed breakthrough GPCR protein crystallization/structure determination technology from The Scripps Research Institute (TSRI) that was featured on the cover of Science in 2007 ("Technology") and has made significant advances to industrialize and apply the Technology to the discipline of drug discovery and development. The Technology is a central component of Receptos' drug discovery engine which is focused on delivering best-in-class and first-in-class GPCR therapeutic candidates.

## Best-in-Class Sphingosine-1-Phosphate 1 (S1P1) Receptor Agonist RPC1063 Program in Phase 1 Clinical Study

Receptos has developed a highly selective S1P1 agonist candidate (RPC1063) and has entered a single-ascending and multiple-ascending dose design Phase 1 clinical safety study under a US Investigational New Drug (IND) application. The study will generate data to confirm that the characteristics of RPC1063 meet pre-specified pharmacokinetic (PK), pharmacodynamic (PD), and safety criteria. These include half-life determination to support once-per-day dosing and measures that will focus on extent and speed of reversibility of lymphopenia. Safety features will also include observation of cardiovascular, hepatic, lung, and ocular events. The goal of the Phase 1 study will be to utilize the PK-PD relationship of RPC1063 to accurately select dose levels for Phase 2/3 evaluation. The Phase 1 study is anticipated to conclude in Q1 2012, paving the way for planned Phase 2/3 pivotal study initiation in 2012.

RPC1063, developed in the labs of Receptos, is a novel, highly selective S1P1 agonist exhibiting picomolar potency that is effective in rodent models of multiple sclerosis, and possesses an excellent safety profile in non-clinical toxicology studies. In addition to selectivity, which reduces the likelihood of "off target" side effects, RPC1063 has an appropriately short half-life to promote rapid reversibility of lymphopenia. RPC1063 will be investigated in the preclinical and clinical setting in other immune-mediated disorders, including inflammatory bowel disease (IBD).



S1P1 is a G protein-coupled receptor (GPCR) that binds the lipid signaling molecule sphingosine 1-phosphate (S1P). S1P is a circulating lipid that binds to five GPCRs termed S1P1-5. S1P1 selectively regulates physiological functions in the immune and cardiovascular systems, including immune cell trafficking and the maintenance of endothelial integrity. In the disease state of multiple sclerosis, S1P1 agonism works by selectively sequestering circulating lymphocytes, blunting the underlying autoimmune cause of multiple sclerosis.



## Receptos Company Overview

Founded in 2009

Privately held and San Diego based

\$25MM Series A backed by ARCH Venture Partners, Flagship Ventures, Lilly Ventures, and Venrock

Exclusive rights from The Scripps Research Institute (TSRI)

Proven Founder and Management track record for success

## Management Team

Faheem Hasnain, President and CEO

Marcus F. Boehm, Ph.D., Chief Technical Officer and co-Founder

Sheila Gujrathi, M.D. Chief Medical Officer

Chrysa Mineo, Vice President, Corporate Development

Robert J. Peach, Ph.D., Chief Scientific Officer and co-Founder

James R. Schmidt, CPA, Vice President, Finance and Administration

## Scientific Founders

Hugh Rosen, M.D., Ph.D., Professor, TSRI

Raymond C. Stevens, Ph.D., Professor, TSRI

## Pipeline Driven by Transformational GPCR Drug Discovery Technology

GPCR receptors are the largest single drug discovery protein family, yet many high-value targets have been intractable to traditional drug discovery techniques. Receptos offers a paradigm-shifting Technology enabling for the first time structure-based drug design for this important target class. This unique offering delivers novel drug discovery tools along the path to structure determination including the generation of purified GPCR protein (to allow biophysical ligand screening and therapeutic antibody candidate generation), the identification of novel receptor binding sites, including allosteric sites (to confer improved potency and selectivity profiles to drug candidates), and GPCR structure determination to transform drug discovery.

## Information-Driven Drug Discovery Integrating GPCR Crystallization



## GPCR Structural Biology Platform Provides Diverse Partnering Options with Receptos

Corporate Partnering is a key component of the Receptos strategy to drive best-in-class and first-in-class therapeutic GPCR candidates into clinical development. Receptos collaborates on the topics of both drug discovery and GPCR structure-determination technology. Key features of collaboration with Receptos may include:

- Delivery of high quality, stable and functional GPCR protein for biophysical ligand screening
- Exclusive Drug Discovery & Development
- Technology Transfer

**Receptos has entered into technology partnerships with Eli Lilly, Ono Pharmaceutical, and the Ortho-McNeil-Janssen subsidiary of Johnson & Johnson.**

For more information, please contact Chrysa Mineo, Vice President of Corporate Development at: [cmineo@receptos.com](mailto:cmineo@receptos.com)

## Board of Directors

William H. Rastetter, Ph.D., Chairman of the Board and co-Founder

Faheem Hasnain, President and CEO

Fred Aslan, M.D. Vice President, Venrock

Kristina Burow, Partner of ARCH Venture Partners

Doug Cole, M.D., General Partner of Flagship Ventures

Raymond C. Stevens, Ph.D., Professor, TSRI

S. Edward Torres, Managing Director at Lilly Ventures

## Clinical Advisory Board

David Essayan, M.D., FACP, EVP, Oncord, Inc.

Stephen Hauser, M.D., Chairman, Department of Neurology, UCSF

Alan Nies, M.D., President, Nies Consulting

Hugh Rosen, M.D., Ph.D., Professor, TSRI

Lawrence Steinman, M.D., Professor, Department of Neurology, Stanford University

Eric Topol, M.D., Director, Scripps Translational Science Institute, Professor, TSRI

## Contact

Receptos, Inc.  
10835 Road to the Cure, Suite 205  
San Diego, CA 92121  
P 858.652.5700  
F 858.587.2659  
E [info@receptos.com](mailto:info@receptos.com)  
W [www.receptos.com](http://www.receptos.com)